CONGRESSWOMAN ELISE STEFANIK
On Monday, September 15, 2014, the House will consider H.R. 4771, the Designer Anabolic Steroid Control Act, as amended, under a suspension of the rules. H.R. 4771 was introduced on May 29, 2014 by Rep. Joe Pitts (R-PA) and referred to the Committee on Energy and Commerce, which ordered the bill reported, as amended, by voice vote.
H.R. 4771 amends the Controlled Substances Act to expand the list of anabolic steroids regulated by the Drug Enforcement Administration (DEA) by twenty-five new substances. Moreover, this legislation authorizes the Attorney General to, by rule, issue a permanent order adding a drug or other substance to the definition of anabolic steroids if such drug satisfies the criteria for being considered an anabolic steroid under the Controlled Substances Act. This legislation also establishes penalties for the false labeling of anabolic steroids. Finally, H.R. 4771 allows the Attorney General to collect data and analyze products to determine whether they contain anabolic steroids and are properly labeled in accordance with this Act. The Attorney General may also publish in the Federal Register or on the DEA website a list of products that have been determined to contain an anabolic steroid and are not labeled in accordance with this Act.
This legislation would “close a loophole often exploited by steroid manufacturers to sell products that claim to be all-natural muscle builders when they may actually contain chemically altered versions of anabolic steroids.” By granting the DEA authority to schedule new drugs on the controlled substances list, it will allow the Agency to identify and list new chemicals more easily.
CBO estimates that implementing this legislation would have no significant costs to the federal government. Enacting this legislation could have an effect on direct spending and revenues, but CBO estimates that any effects would be insignificant for each year.
For questions or further information contact the GOP Conference at 5-5107.